PCOS Healthcare Trends · Evergreen explainer
Hirsutism: excess hair growth, explained without embarrassment
For a lot of people, this is the symptom they mention last, quietly, at the end of a visit, if they mention it at all. Coarse, dark hair growing on the upper lip, chin, chest, abdomen or back can feel embarrassing to describe out loud. Clinicians have a plain name for it, hirsutism, and in PCOS, now also called PMOS for polyendocrine metabolic ovarian syndrome, it matters medically. It is one of the visible signs of androgen excess, which is one of the three features used to diagnose this condition. This piece explains what hirsutism is and what it is not, how clinicians grade it, why the number that counts as hirsutism is lower than many older pages suggest, and which changes in hair growth should lead to a different, faster workup.
What hirsutism means, in plain words
Hirsutism means excess growth of terminal hair in areas of the body that respond to androgens. Terminal hair is the coarse, darker, longer kind. The guideline describes it as hair that would grow beyond about 5 millimetres if left alone, pigmented, and different in texture from fine vellus hair, the soft, light hair most people have across much of the body. Our glossary defines hirsutism, androgens and related terms in plain language.
Location matters as much as amount. The areas clinicians pay attention to are the androgen-sensitive ones: upper lip, chin, chest, upper and lower abdomen, upper and lower back, upper arms and thighs. Hair on the forearms or lower legs, by contrast, is usually described differently. Clinicians use the word hypertrichosis for generalised excess hair in areas that do not depend on androgens. The distinction sounds technical, but it changes what a clinician looks for next, which is why naming where the hair is, and when it changed, helps more than a general statement that there is more hair.
Hirsutism on its own is a sign, not a diagnosis. PCOS/PMOS is the most common condition linked to it, but it is not the only one, and a workup still has to consider other causes first. Our explainer on how PCOS/PMOS is diagnosed sets out that rule-out step and the 2-of-3 rule the sign feeds into.
The androgen link
Androgens are a group of hormones present in all sexes. In this condition, higher androgen levels, or follicles that respond more strongly to usual levels, can shift fine hair toward coarse terminal hair in those sensitive areas. Extra insulin can be part of that picture too, because it can raise androgen activity and lower SHBG, the protein that keeps some androgen inactive. Our explainer on insulin resistance in PCOS/PMOS walks through that link in plain steps.
The 2023 International Evidence-based Guideline makes a specific point about weight in this chain that is worth knowing: hirsutism alone, in an adult, should be considered predictive of biochemical hyperandrogenism and of PCOS. By contrast, the guideline says acne on its own and female pattern hair thinning on its own, without hirsutism, are relatively weak predictors of biochemical hyperandrogenism. That ranking does not make acne or thinning unimportant. It tells you why a clinician who hears about excess hair growth should take the next steps seriously, even if blood results and other features are still being gathered. Our piece on the four PCOS/PMOS phenotypes shows where androgen excess sits among the three diagnostic features.
How clinicians grade it: the Ferriman-Gallwey score
The standard visual tool is the modified Ferriman-Gallwey score, often shortened to mFG. A clinician looks at nine areas, the list above, and grades each one from 0, no terminal hair, to 4, extensive terminal growth. Added together, the total runs from 0 to 36. It is a structured way to record what is seen, so change over time can be compared visit to visit, rather than left as a vague note.
Three limits belong next to that description, and good explainers state them up front. First, scoring depends on the observer, so two clinicians may grade the same pattern a point or two apart. Second, cosmetic hair removal hides the sign. The guideline notes this directly: many people remove hair before an appointment, so what is visible in the room can look milder than what the person lives with. Third, a score is a snapshot. When the hair appeared, how fast it changed, and whether cycles or other features changed alongside it are part of the assessment too, which is why a dated history matters. Our guide to questions to bring to a first appointment shows how to prepare that record.
What number counts: 4 to 6, and why background matters
Older pages and older guidelines often quote 8 as the cutoff. The 2023 international guideline lowered the working range: it says a modified Ferriman-Gallwey score of 4 to 6 should be used to detect hirsutism, with the exact point inside that range depending on ethnic background, because usual terminal hair growth varies across populations while the prevalence of hirsutism itself appears broadly similar.
A 2025 study in the European Journal of Endocrinology tested that range against population data. The PCOS Phenotype in Unselected Populations study pooled directly assessed scores from 9,829 unselected participants aged 18 to 45, drawn from 12 community studies in 8 countries, and used cluster analysis to derive normative cutoffs by ethnic group. The authors reported cutoffs ranging from 4 to 8: 8 in White Iranian participants, 7 in White Italian and Black African participants, 5 in Asian Han Chinese, White Russian, Turkish and Black American participants, and 4 in White American, Asian Korean, Asian Russian and Mixed Russian participants. Their conclusion was that the findings confirm the guideline range of 4 to 6 for the majority of populations studied, with a few exceptions, and that clinicians should consider ethnicity when they apply a cutoff.
Read that study the way its design requires. It is population data, useful for setting a threshold, not a test you apply to yourself at home to settle a diagnosis. A self-score can help you describe what you see, but hair removal, lighting, and the difference between vellus and terminal hair make home scoring rough, and a diagnosis still needs the full pattern, other causes considered, and, where the guideline directs it, blood work. If your score sits near a boundary, that is a conversation to have explicitly, not a reason to dismiss the sign or to settle it alone.
Your own report counts
The guideline is unusually direct on this point, and it is the sentence many patients wish they had known earlier. It says healthcare professionals should be aware of the potential negative psychosocial impact of clinical hyperandrogenism, and should consider a report of unwanted excess hair growth, or female pattern hair loss, as important regardless of apparent clinical severity. In its supporting text, it also notes that self-assessment of unwanted hair growth has validity and merits close evaluation, even when overt signs are not readily evident on examination.
In plain terms: if you removed hair that morning, if the growth that distresses you sits in an area the nine-area scale does not capture well, such as the sideburns or neck, or if the amount looks small to someone else but takes daily time and money to manage, saying so is part of the clinical record, not a side comment. The Endocrine Society guideline on hirsutism uses a related idea, patient-important hirsutism, for hair growth that causes distress even when a score is not abnormal. Both guidelines are making the same practical point from different angles: severity in a life is not only a number on a chart.
Patterns that need a different workup
Most hirsutism linked to this condition develops gradually, often from around puberty onward, and travels with other features such as irregular cycles. A different pattern should change the conversation. Based on what the 2023 guideline and the Endocrine Society guideline direct clinicians to consider, tell a clinician promptly, and expect a broader workup, if you notice:
- Sudden onset or rapid progression over months, rather than a slow change over years.
- Signs clinicians group under virilisation, such as a deepening voice, increasing muscle bulk, scalp hair loss at the front with a receding pattern, or enlargement of the clitoris. These are uncommon, and they point away from routine PCOS assessment toward urgent evaluation for other androgen sources.
- Very high androgen results if blood work has been done. The 2023 guideline says that when androgen levels are markedly above the laboratory reference range, causes other than PCOS should be considered, including growths of the ovary or adrenal gland, congenital adrenal hyperplasia, Cushing syndrome, ovarian hyperthecosis after menopause, medicine-related causes, and syndromes of severe insulin resistance.
- A pattern that does not fit, for example hirsutism with regular cycles and no other feature, or hirsutism alongside missed periods that began abruptly, galactorrhoea, or new severe acne. A complete workup still has to sort thyroid, prolactin, adrenal and other look-alike causes, as our diagnosis explainer describes.
That list is general information about what guidelines tell clinicians to watch for. It is not a way to diagnose yourself, and it does not rank your own risk. If any of it matches what you are seeing, the useful step is a timely appointment where you can name the timeline in dates.
Which clinician handles which part
There is rarely one owner for this sign, and knowing the division helps you ask for the right referral:
- Primary care or OB-GYN usually starts the workup: the history and examination, the Ferriman-Gallwey grading, the first blood work the guideline directs, and the check for other causes.
- An endocrinologist is the clinician who leads when androgen excess needs deeper sorting, when results are markedly high, when an adrenal or other endocrine cause is in question, or when metabolic screening needs coordinating.
- A dermatologist handles the skin side: confirming what kind of hair growth is present, sorting acne and scalp changes that travel with it, and discussing the dermatologic and cosmetic options that sit in their lane. What any option does for a given person is a decision for that visit. This page makes no claim about it.
- Mental health support belongs in the picture when the impact is heavy. The guideline treats psychological features as part of assessment in this condition, not as an afterthought, and distress about hair growth is one of the places that shows up most plainly.
Our piece on which clinician does what maps that team in full, including dietitians and reproductive endocrinologists.
What this does not mean
- Hirsutism alone is not a PCOS diagnosis. It is one feature. The diagnosis needs the pattern, and other causes considered first.
- A low score does not erase a real concern. Hair removal, ethnic variation, and areas outside the nine-area scale can all make a score look lower than the lived pattern. The guideline instruction is to treat the report as important regardless of apparent severity.
- More hair does not mean higher androgens in a straight line for every person. Follicle sensitivity varies, so visible growth and blood results do not always move together. That is why clinicians use both the clinical sign and, where directed, biochemical testing.
- This page names no treatment as right for you. It gives no doses, ranks no product or procedure, and describes no result you should expect. Those decisions depend on your full workup, whether pregnancy is a goal, and your own priorities, made with your clinician.
Questions to bring to an appointment about excess hair growth
- Can we record a Ferriman-Gallwey grade today, and can I tell you what hair removal I did before this visit so the grade is read in context?
- Given my background, which cutoff in the 4 to 6 range are you applying to me, and what does my grade mean alongside my cycle pattern?
- Do I need blood work for androgen levels, and if so, which tests, and how does being on hormonal contraception affect how we read them?
- What other causes have we considered for this pattern, and what would make us look further, for example toward an adrenal cause?
- Has anything in my timeline, sudden onset, rapid change, or other new signs, changed how urgently we should work this up?
- Should dermatology be part of my care, and who coordinates between dermatology, endocrine and my main clinician?
- Can the impact this is having, time, cost, and distress, be written into my record, not only the score?
What this means when you are finding care
The clinician you want can grade the sign properly, name the cutoff they are using and why, explain what blood work adds, and state plainly what would make them look for a different cause. You can search the directory for PCOS/PMOS-focused providers by state, provider type and telehealth, browse by state, for example the Florida listings page, and skim the plain-language glossary before a visit.
Sources
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, Journal of Clinical Endocrinology and Metabolism, 2023, including sections 1.2 and 1.3 on biochemical and clinical hyperandrogenism (hirsutism alone as predictive, Ferriman-Gallwey cutoff of 4 to 6, psychosocial impact, and markedly high androgens prompting consideration of other causes) — read the guideline (PMC)
- Bizuneh AD, et al. The PCOS Phenotype in Unselected Populations study: ethnic variation in population-based normative cut-offs for defining hirsutism, European Journal of Endocrinology, 2025;192:228-239 (9,829 participants, 12 studies, 8 countries; cutoffs 4 to 8 by ethnic group) — read the study abstract (PubMed) · publisher page (DOI)
- Martin KA, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology and Metabolism, 2018;103:1233-1257 (definition of hirsutism, Ferriman-Gallwey grading in nine areas, and patient-important hirsutism) — read the guideline summary (PMC)
- The guideline programme home at Monash University — Monash Centre for Health Research and Implementation, PCOS
- Federal overview of the condition — NICHD, PCOS topic page
Looking for care? Find a PCOS/PMOS-focused provider or browse by state.
This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.